In situ mesothelioma needs to be diagnosed by immunohistochemical detection of BAP1 and/or MTAP loss, and/or by fluorescence in situ hybridization detection of CDKN2A homozygous deletion, and fully discussed with thoracic surgeons and radiologists in MDT. Here, CDKN2A is linked to mesothelioma.